

Appendix 4C

Quarter Ended 30 September 2023

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM

ASX ANNOUNCEMENT **31 OCTOBER 2023**

QUARTERLY ACTIVITIES REPORT FOR THE PERIOD ENDING 30 SEPTEMBER 2023

Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 30 September 2023.

Highlights for the quarter included:

- Clinical study agreement with MD Anderson Cancer Center for Phase 1B study of CHM 0201 in newly diagnosed Acute Myeloid Leukemia (AML)
- Completion of CHM 1101 (CLTX CAR T) Phase 1A dose escalation in in recurrent/ progressive brain cancer
- Positive in vitro data for CHM 0301
- Patent allowance for chlorotoxin in Japan
- Mr Eric Sullivan appointed to Board of Directors
- US$3m introduction fee received

Clinical study agreement with MD Anderson for Phase 1B study of CHM 0201 in newly diagnosed AML

In September the Company announced the execution of a clinical study agreement with The University of Texas MD Anderson Cancer Center to support the "ADVENT-AML" Phase 1B study, in which Chimeric's off-the-shelf universal donor NK cell therapy CHM 0201 will be evaluated in combination with standard of care therapy for patients with newly diagnosed Acute Myeloid Leukemia (AML).

The ADVENT-AML (NCT05834244) study is designed to enroll up to 20 subjects with newly diagnosed AML who are not eligible for intensive chemotherapy or allogeneic stem cell transplant, following completion of a dose confirmation cohort assessing the safety of this novel combination treatment in subjects with relapsed or refractory AML. ADVENT-AML will be the first trial to evaluate the synergy of NK cell therapy in combination with the current standard of care of Azacitidine with Venetoclax (AZA-VEN).

As the trial progresses beyond dose confirmation, it will also be the first trial to evaluate cellular therapy in newly diagnosed AML patients. The study, which has received IND clearance by the FDA and is expected to open to enrollment at MD Anderson by year end 2023, will be led by

Principal Investigator Abhishek Maiti MD, Assistant Professor in the Department of Leukemia at MD Anderson.

Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults with a median age at diagnosis between 65-72 years. Despite treatment advances, patients who are not eligible for intensive chemotherapy or allogeneic stem cell transplant patients have limited therapeutic options.

Chimeric's CEO and Managing Director Jennifer Chow, Chief Medical Officer Dr Jason B. Litten, with Dr Maiti, hosted a webinar regarding this announcement and the Phase 1B trial.[1]

Completion of CHM 1101 (CLTX CAR T) Phase 1A dose escalation in brain cancer

The Company was pleased to announce the successful treatment of the third participant, required to complete the fourth and final planned dose escalation cohort, in a Phase 1A dose escalation study being conducted at City of Hope evaluating the safety and maximum tolerated dose of Chimeric's CHM 1101 (CLTX CAR T) in patients with recurrent or progressive glioblastoma (GBM).

The Phase 1A study enrolled clinical trial participants with MMP2+ recurrent or progressive GBM across four dose levels. Study objectives were to evaluate the safety and efficacy of CLTX CAR T and to establish recommended dosing for a Phase 2 trial. Participants at this dose level received a total dose of 440 X 106 CHM 1101 (CLTX CAR T) cells through dual routes of intratumoral and intraventricular administration.

In parallel Chimeric has advanced development of CHM 1101 to a Phase 1B clinical trial at the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center in Austin, Texas.

The trial is being conducted under a US IND and is a two-part clinical trial designed to determine a recommended Phase 2 dose and administration schedule. Part A of the trial will enroll 3-6 clinical trial participants at the highest dose tested in the Phase 1A clinical trial at City of Hope.

In late 2023, Chimeric will provide an update on the clinical safety and activity from the CHM 1101 clinical program. Based on a favorable review of the results of that assessment, Part B of the trial, a dose expansion cohort, will be opened to enroll 12 to 26 additional participants.

[1] Watch the video at: https://www.youtube.com/watch?v=sQdVtJlo75Y

Positive in vitro data for CHM 0301

During August Chimeric announced positive in vitro data for CHM 0301, its next generation armored natural killer (NK) cell platform.

The CHM 0301 NK cell platform builds on the foundation of CHM 0201, which has previously demonstrated safety and early signs of clinical activity in Acute Myeloid Leukemia (AML) and Colorectal Cancer (CRC) patients. It is now being evaluated in the first clinical trial to combine NK cells with Vactosertib, an oral TGFβ receptor inhibitor.

The CHM 0301 NK cell platform engineers CHM 0201 cells with two "armoring" enhancements designed to maximise potency and enable the cells to overcome immune-suppressive tumour microenvironments. CHM 0301 cells express a dominant-negative TGFβ receptor molecule on the cell surface and secrete the immunostimulatory cytokine interleukin 15 (IL-15).

When evaluated in in vitro models of human AML and CRC, CHM 0301 demonstrated significant enhancement of TGFβ resistance and potency compared to first generation CHM 0201 cells.

- >3x more resistant to suppression by TGFβ
- Up to ~25% relative increase in potency in the absence of TGFβ
- Up to ~80% relative increase in potency in the presence of TGFβ

Additional experiments are ongoing to further characterise the behavior and activity of CHM 0301 and to introduce Chimeric's CLTX and CDH17 CARs into its NK cell platform as part of the CHM 1301 and CHM 2301 CAR NK programs.

Patent allowance for chlorotoxin in Japan

During July Chimeric announced that the Japan Patent Office issued a Notice of Allowance for application JP2022007016A, which covers certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including Chimeric's clinical-stage CAR T asset CHM 1101 and preclinical stage CAR NK asset CHM 1301.

Initial patent protection for CLTX CAR technology in Japan was granted in 2022 under patent number JP 7,085,990. The newly allowed application, JP2022007016A, expands the scope of patent protection to cover a broader range of CLTX CAR construct designs.

Chimeric holds the exclusive worldwide license to develop and commercialize JP2022007016A, under patent number JP 7,085,990, and related patent applications filed in other global territories.

Board changes

Mr Eric Sullivan joined Chimeric's Board as a Non-Executive Director during the period. Mr Sullivan is a senior finance and operations leader with a focus on private-to-public biotechnology company building, strategy, fundraising and financial planning.

He brings with him an impressive background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of high-growth public biotech companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics. Additionally, his experience with blue-chip private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics, further underpins his expertise in financial planning, fundraising, board management and investor relations.

Mr Sullivan replaced the outgoing Ms Cindy Elkins, who stepped down from the Board after serving during the formative years of Chimeric.

Ms Leslie Chong resigned from her position as Non-Executive Director to focus on her duties as Chief Executive Officer of Imugene Limited. Leslie served on the Chimeric Board since August 2020. Following her resignation, the Board appointed Mr Phillip Hains to fill a casual vacancy. Phillip is the Company's CFO and Joint Company Secretary and Principal of Melbourne based "The CFO Solution".

Later, Mr George Matcham resigned as a Non-Executive Director, having served since July 2021.

Finance update

Following the execution of definitive documentation between Imugene Limited and Precision Biosciences, Inc, related to the research and development of the azer-cel CAR T technology, Imugene was obliged to pay Chimeric an introduction fee of US$3 million (approximately A$4.4 million). This capital will be used to continue advancement of Chimeric's transformational cell therapy platform.

The Appendix 4C Quarterly Cash Flow report is set out below.

As detailed in the Appendix 4C, the Company had $4.6 million in cash at the end of the quarter, increasing from $2.4 million at the end of the prior quarter. As announced on 16 August 2023, Chimeric received an introduction fee of A$4.4 million (USD$3 million) excluding GST.

Net Cash used in Operating Activities during the quarter amounted to $0.3 million. Staff costs and direct Research and Development expenditure accounted for over 83% of total operating

payments. Included in the payments were a number of one-off expenditure items such as $1.0 million in clinical start-up costs, and payment of accrued expenses for 30 June.

Gross funds in Financing activities includes $3 million banked on July 3rd from the Share Placement Agreement with Lind Global Fund II LP.

In accordance with Listing Rule 4.7C disclosure, payments made to related parties and their associatesincluded in items 6.1 of the Appendix 4C include payments for remuneration of direct or fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses.

The company has focused expenditure on projects that will deliver milestones for the company and to preserve available resources and has reduced the operating headcount in line with priorities and deferred discretionary expenditure.

Over the past 6 months we have focused on reducing cash burn with expense reductions across a number of areas:

- Headcount in January 2023 was 13 people, and as at 31 September 2023 it had been reduced to 6 people
- Cash flow management removing office space and reducing consultants
- Program prioritization with a focus on clinical development
- Collaborative clinical development with academic institutions to advance clinical trials with nominal cost to CHM
- The Chairman has deferred his fees from April this year and the Board has also agreed to defer their fees until further notice

As recently announced, the company is undertaking a $10 million Rights Issue. Coupled with our cash on hand, and the R&D rebate of $3.6m, this will place us in a position to execute on our clinical development program.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 current clinical programs and plans to open additional clinical programs in 2024.

CHM 1101 (CLTX CAR T) is a first in class CLTX CAR T that has demonstrated positive Phase 1A clinical results. Heavily pretreated patients, on average being treated in 4th line, achieved a 55% Disease Control Rate (DCR). Those patients that achieved disease control demonstrated a median of 9.9 months survival, with two patients achieving 14 + months survival with one in ongoing follow up. Safety demonstrated a manageable profile with no DLT's, no CRS and no TLS. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent/ progressive glioblastoma which, based upon the positive Phase 1A clinical data, will now advance to an expansion cohort

CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.

CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CHM 0201 in combination are now underway. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Executive Chairman Paul Hopper.

CONTACT

Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
Chimeric Therapeutics
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Chimeric Therapeutics Limited	
ABN	**Quarter ended ("current quarter")**
68 638 835 828	30 September 2023

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers (inclusive of GST)	5,475	5,475
1.2	Payments for (inclusive of GST)		
	(a) research and development	(2,485)	(2,485)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs*	(2,409)	(2,409)
	(f) administration and corporate costs	(907)	(907)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	14	14
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	
1.8	Other (provide details if material)	29	29
1.9	**Net cash from / (used in) operating activities**	**(283)**	**(283)**

*Staff costs includes staff, directors, scientific advisors and employment related costs.

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	3,100	3,100
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(626)	(626)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other – payments of licence fee liabilities	-	-
3.10	**Net cash from / (used in) financing activities**	**2,474**	**2,474**

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	2,363	2,363
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(283)	(283)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	2,474	2,474
4.5	Effect of movement in exchange rates on cash held	(2)	(2)
4.6	**Cash and cash equivalents at end of period**	**4,552**	**4,552**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000***
5.1	Bank balances	4,052	2,363
5.2	Call deposits	500	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**4,552**	**2,363**

* As disclosed in the 30 June 2023 Annual Report, $3.01m that was classified as cash and cash equivalents in the June Quarter 4C, was recoded as trade & other receivables.

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	528
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Item 6.1 – Include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	**-**	**-**

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(283)
8.2	Cash and cash equivalents at quarter end (item 4.6)	4,552
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	4,552
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	16

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: The operating cash inflow for this period included a one-off receipt from customers of $5.5m (Including GST) of which approximately $4.4m (excluding GST) relate to an introduction fee from Imugene Limited which was announced on 16 August 2023. The Board and management will continue to assess alternative capital sources and continue to employ cash management strategies such as delaying discretionary operating activities.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: The Board is assessing alternative capital sources and the Directors believe that the Company can raise sufficient capital based on the success of previous capital raises and the continued development of the Company's projects. In addition, the Company has and will continue to employ cash management strategies such as delaying discretionary operating activities.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: The Board is assessing alternative capital sources and the Directors believe that the Company can raise sufficient capital based on the success of previous capital raises and the continued development of the Company's projects. In addition, the Company has and will continue to employ cash management strategies such as delaying discretionary operating activities.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

* Refer to responses in section 8.6.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 31 October 2023

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

Phone +61 3 98245254
Email info@chimerictherapeutics.com

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM

CHIMERIC THERAPEUTICS